132 related articles for article (PubMed ID: 18450737)
21. FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin's lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation.
Nishio M; Endo T; Fujimoto K; Yamamoto S; Obara M; Yamaguchi K; Takeda Y; Goto H; Kasahara I; Sato N; Koike T
Eur J Haematol; 2009 Feb; 82(2):143-7. PubMed ID: 19018870
[TBL] [Abstract][Full Text] [Related]
22. Emerging treatments for indolent lymphoma.
Cheson BD; Gregory SA; Marcus R
Clin Adv Hematol Oncol; 2007 May; 5(5 Suppl 8):1-9; quiz 11-2. PubMed ID: 17637594
[TBL] [Abstract][Full Text] [Related]
23. Importance of fluorodeoxyglucose-positron emission tomography (FDG-PET) and endoscopic ultrasonography parameters in predicting survival following surgery for esophageal cancer.
Omloo JM; Sloof GW; Boellaard R; Hoekstra OS; Jager PL; van Dullemen HM; Fockens P; Plukker JT; van Lanschot JJ
Endoscopy; 2008 Jun; 40(6):464-71. PubMed ID: 18543134
[TBL] [Abstract][Full Text] [Related]
24. Radioimmunotherapy of refractory or relapsed Hodgkin's lymphoma with 90Y-labelled antiferritin antibody.
Decaudin D; Levy R; Lokiec F; Morschhauser F; Djeridane M; Kadouche J; Pecking A
Anticancer Drugs; 2007 Jul; 18(6):725-31. PubMed ID: 17762404
[TBL] [Abstract][Full Text] [Related]
25. Inroads in the therapy of indolent lymphomas: exploiting biological insights.
McLaughlin P
Cancer Invest; 1999; 17(1):73-86. PubMed ID: 10999051
[No Abstract] [Full Text] [Related]
26. Treatment approaches and nursing considerations for non-Hodgkin's lymphoma.
Long J; Versea L
Semin Oncol Nurs; 2006 May; 22(2):97-106. PubMed ID: 16720232
[TBL] [Abstract][Full Text] [Related]
27. GM1 expression of non-Hodgkin's lymphoma determines susceptibility to rituximab treatment.
Meyer zum Büschenfelde C; Feuerstacke Y; Götze KS; Scholze K; Peschel C
Cancer Res; 2008 Jul; 68(13):5414-22. PubMed ID: 18593944
[TBL] [Abstract][Full Text] [Related]
28. Rituximab: converging mechanisms of action in non-Hodgkin's lymphoma?
Eisenbeis CF; Caligiuri MA; Byrd JC
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5810-2. PubMed ID: 14676100
[No Abstract] [Full Text] [Related]
29. Antibody and immunomodulatory agents in the treatment of indolent non-Hodgkin's lymphoma.
LaCasce AS; Freedman AS
Semin Hematol; 2008 Apr; 45(2):85-9. PubMed ID: 18381102
[TBL] [Abstract][Full Text] [Related]
30. Practical and clinical benefits of radioimmunotherapy lead to advantages in cost-effectiveness in the treatment of patients with non-Hodgkin's lymphoma.
Otte A; Thompson SL
Nucl Med Commun; 2006 Oct; 27(10):753-6. PubMed ID: 16969255
[No Abstract] [Full Text] [Related]
31. ECOG 4402: randomized phase III-trial comparing two different rituximab dosing regimens for patients with low tumor burden indolent non-Hodgkin's lymphoma.
Williams ME
Curr Hematol Rep; 2004 Nov; 3(6):395-6. PubMed ID: 15496271
[No Abstract] [Full Text] [Related]
32. Potential of immuno-positron emission tomography for tumor imaging and immunotherapy planning.
Zalutsky MR
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1958-60. PubMed ID: 16609003
[No Abstract] [Full Text] [Related]
33. Non-Hodgkin's lymphomas: understanding monoclonal antibody therapy.
Hendrix C
ONS News; 2006; 21(8 Suppl):19-20. PubMed ID: 16925135
[No Abstract] [Full Text] [Related]
34. [Radio-immunotherapy for B-cell non-Hodgkin lymphoma].
Visser OJ; Zijlstra JM; van Dongen GA; Huijgens PC
Ned Tijdschr Geneeskd; 2005 Oct; 149(42):2324-8. PubMed ID: 16261710
[TBL] [Abstract][Full Text] [Related]
35. The expanding frontier of radioimmunotherapy of relapsed Non-hodgkin's lymphoma.
Kozuch P; Grossbard ML
Clin Lymphoma; 2000 Sep; 1(2):158-9. PubMed ID: 11707826
[No Abstract] [Full Text] [Related]
36. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma patients.
Coiffier B
Haematologica; 1999 Jun; 84 Suppl EHA-4():14-8. PubMed ID: 10907457
[No Abstract] [Full Text] [Related]
37. A simple and safe method for 131I radiolabeling of rituximab for myeloablative high-dose radioimmunotherapy.
Tran L; Baars JW; Maessen HJ; Hoefnagel CA; Beijnen JH; Huitema AD
Cancer Biother Radiopharm; 2009 Feb; 24(1):103-10. PubMed ID: 19243252
[TBL] [Abstract][Full Text] [Related]
38. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma: moving targets.
van Oers MH
Neth J Med; 2009 Sep; 67(8):309-10. PubMed ID: 19767656
[No Abstract] [Full Text] [Related]
39. A revolution in the treatment of non-Hodgkin's lymphoma.
DeNardo GL; O'Donnell RT; Oldham RK; DeNardo SJ
Cancer Biother Radiopharm; 1998 Aug; 13(4):213-23. PubMed ID: 10850358
[TBL] [Abstract][Full Text] [Related]
40. A possible role of 18F-FDG positron-emission tomography scanning in the early detection of rituximab-induced pneumonitis in patients with non-Hodgkin's lymphoma.
Nieuwenhuizen L; Verzijlbergen FJ; Wiltink E; Grutters JC; Biesma DH
Haematologica; 2008 Aug; 93(8):1267-9. PubMed ID: 18556403
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
